The potential role of TOFAs in the treatment of RA also emerged from the results of several studies that analyzed the best treatment strategy for RA patients who were refractory to initial second-line therapy with anti-tumor necrosis factor-α (TNFα) bDMARDs. This evidence concerns the gene TNF and rheumatoid arthritis.